Study S002827

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Insulin Glargine s.c. Once Daily in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Inadequately Controlled on 1-3 Oral Glucose-lowering Medications (AMBITION 7)

ClinicalTrials.gov record

Registration

Registration: NCT07797335
Acronym: AMBITION 7
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 1778
Start: 2026-08-24
Primary completion: 2028-07-31
Lead sponsor: Novo Nordisk A/S
Conditions: Type 2 Diabetes; Cardiovascular Risk
Interventions: DRUG:Zenagamtide; DRUG:Insulin glargine U-100
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1333-6446; OTHER:2026-525209-11

Registered primary outcomes

Non-inferiority of zenagamtide versus insulin glargine: change in haemoglobin A1c (HbA1c) [From baseline (week 0) to week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.